Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meng-Jiao, He, Qing, Li, Mei, Luo, Feng, Guan, Yong-Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790503/
https://www.ncbi.nlm.nih.gov/pubmed/27022285
http://dx.doi.org/10.2147/OTT.S80635
Descripción
Sumario:Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. This paper reviews its role in the targeted treatment of NSCLC in Chinese patients.

Ejemplares similares